



Zohydro[®] ER (hydrocodone) – First-time authorized brand alternative

- On January 2, 2020, Macoven launched an authorized brand alternative of Currax's [Zohydro ER \(hydrocodone\)](#) extended-release capsules.
- Zohydro ER is approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
- Zohydro ER carries a boxed warning for addiction, abuse, and misuse; risk evaluation and mitigation strategy; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction; risks from concomitant use with benzodiazepines and other central nervous system depressants; and interaction with alcohol.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.